Bryant v. Stein et al.

Why this Matters:

The plaintiff alleges that North Carolina’s legislation, which imposes several requirements to access and prescribe mifepristone, conflicts with the Food and Drug Administration’s (FDA’s) exclusive authority to impose restrictions on the prescribing, dispensing and administration of drugs. In this appeal, intervenor-defendants argue that the district court erred in finding that federal law superseded  North Carolina’s restrictions on mifepristone. 

Potential Impact:

Overriding the FDA’s expertise and preventing individuals from accessing effective medication for abortion services will jeopardize their health and safety.